INDEPENDENT. INTERNATIONAL. LEADERS.
The Research Management Committee (RMC) is made up of independent members whose primary role is to evaluate research proposals and actively help BioCanRx monitor the progress of its projects. The RMC will build and maintain a robust, competitive research portfolio founded on scientific excellence and network goals. All RMC funding and budget recommendations go to the Board of Directors for approval.
In order to avoid potential conflicts of interest, the voting RMC is composed of independent and primarily international experts in biotherapeutics.
Membership
 |
 |
 |
 |
| Dr. Stephen Russell Chair, RMC, Professor, Molecular Medicine Consultant, Hematology Mayo Clinic (USA) |
Dr. Robert Coffin CEO & Director, Replimune |
Awen Gallimore, PhD Professor, Immunology, Infection and Immunity, Cardiff University |
Dr. Jeffrey Hoch Professor, Department of Public Health Sciences, UC Davis |
 |
 |
 |
 |
| Chris Peetz Entrepreneur-in-Residence, Frazier Healthcare/Flashpoint Therapeutics |
Dr. Sumithra Mandrekar Professor of Biostatistics and Oncology at the Mayo Clinic (USA) |
Dr. Grant McFadden Director, Center for Immunotherapy, Vaccines, and Virotherapy Biodesign Institute, Arizona State U, Tempe, AZ (USA) |
Dr. Alan Melcher Professor of Translational Immunotherapy, The Institute of Cancer Research, Chester Beatty Laboratories, London (UK) |
 |
 |
 |
 |
| Dr. Ira Mellman Vice-President, Cancer Immunology, Genentech (USA) |
Dr. Nicole Onetto Former Deputy Director and Chief Scientific Officer, Ontario Institute for Cancer Research (Canada) |
Isabelle Rivière, PhD Director, Michael G. Harris Cell Therapy and Cell Engineering Facility, Molecular Pharmacology at Memorial Sloan Kettering Cancer Center |
Dr. Cliona Rooney Professor, Baylor College of Medicine (USA) |
 |
 |
 |
|
| Dr. Bruce Seet Director, Medical Affairs, Sanofi-Pasteur (Canada) |
Dr. Len Seymour Founder and Chief Scientific Officer, Oxford Genetics (UK) |
Dr. Steven Xanthoudakis Chief Business Development Officer, Quebec Consortium for Drug Discovery (CQDM) |
EX-OFFICIO MEMBERS (NON-VOTING)
Dr. John Bell
BioCanRx Scientific Director
Senior Scientist, the Ottawa Hospital Research Institute
Professor, uOttawa
Dr. Kelvin Chan
Associate Scientist, Sunnybrook Health Sciences Centre (Canada)
Dr. Jason Moffat
BioCanRx Theme Leader
Associate Professor, Canada Research Chair in Functional Genomics of Cancer, University of Toronto
Dr. Brad Nelson
BioCanRx Theme Leader
Director and Distinguished Scientist, Deeley Research Centre, BCCA
Professor, Biochemistry and Microbiology, University of Victoria
Dr. Claude Perreault
Principal Investigator, IRIC
Professor, Faulty of Medicine, Université de Montréal
Hematologist, Maisonneuve-Rosemont Hospital
OBSERVERS
Dr. Stéphanie Michaud
President and CEO, BioCanRx
Dr. Jennifer Quizi
Director, Scientific Affairs, BioCanRx
Alex Pigeon
Senior Program Manager, Networks of Centres of Excellence
